1
|
Golshan M, Wong S, Loibl S, Huober J, O'Shaughnessy J, Rugo H, Wolmark N, McKee M, Maag D, Sullivan D, Metzger-Filho O, Von Minckwitz G, Geyer C, Sikov W, Untch M. Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
2
|
Kolberg H, Tomasevic Z, Demetriou G, Von Minckwitz G, Fujiwara Y, Ponomarova O, Tesch H, Santi P, Hanes V. Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30537-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Untch M, Von Minckwitz G, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J, Hauschild M, Fehm T, Nekljudova V, Loibl S. 1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30755-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Von Minckwitz G. PG 8.03 Clinical usefulness and relevance of intermediate endpoints for cytotoxic primary systemic therapy. Breast 2015. [DOI: 10.1016/s0960-9776(15)70032-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Von Minckwitz G, Darb-Esfahani S, Loibl S, Huober JB, Tesch H, Solbach C, Holms F, Eidtmann H, Diedrich K, Just M, Clemens M, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6 Background: Adjacent ductal carcinoma in situ (DCIS) is in found in approximately 45% of invasive ductal carcinomas (IDC) of the breast. Pure DCIS overexpresses HER2 in approximately 45%. There is uncertainty whether adjacent DCIS impacts on the response to neoadjuvant chemotherapy and trastuzumab as well as whether HER2 expression in IDC component or adjacent DCIS changes throughout treatment. Methods: Core biopsies and surgical tissue from participants of the GeparQuattro study with HER2-positive IDC were centrally examined for the area of invasive ductal component and adjacent DCIS before and after receiving neoadjuvant anthracycline-taxane-trastuzumab containing chemotherapy. HER2 overexpression in IDC and adjacent DCIS was quantified separately by immunohistochemistry using the Ventana automated staining system. Pathological complete response (pCR) was defined as no residual invasive or non-invasive tumor tissue. Results: Fifty nine (37.3%) of 158 IDCs presented with adjacent DCIS at diagnosis. These tumors showed lower regression grades than pure IDC (p=0.033). Presence of adjacent DCIS was an independent negative predictor of pCR (odds ratio 0.42 [95% CI 0.2-0.9], p=0.027). Adjacent DCIS area decreased from pre-treatment to surgery (r=0.205) with 30 (50.8%) IDCs with adjacent DCIS showing complete eradication of adjacent DCIS. HER2 status of adjacent DCIS was highly correlated with HER2 status of IDC component before (r=0.892) and after treatment (r=0.676). Degree of HER2 overexpression of the IDC component decreased in 16 (33.3%) out of 49 patients without a pCR. These 16 IDCs showed lower RGs compared to the 33 IDCs with unchanged HER2 expression (p=0.055). Conclusions: HER2-positive IDCs with adjacent DCIS is less responsive to neoadjuvant chemotherapy and trastuzumab compared to pure IDC. However, complete eradication of adjacent DCIS is frequently observed. HER2-overexpression of the invasive ductal component decreases in a subset of tumors, which showed less tumor regression.
Collapse
Affiliation(s)
- G. Von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - S. Darb-Esfahani
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - S. Loibl
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - J. B. Huober
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - H. Tesch
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - C. Solbach
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - F. Holms
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - H. Eidtmann
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - K. Diedrich
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - M. Just
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - M. Clemens
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - C. Hanusch
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - I. Schrader
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - S. Henschen
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - G. Hoffmann
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - K. Tiemann
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - K. Diebold
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - M. Untch
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| | - C. Denkert
- German Breast Group, Neu-Isenburg, Germany; Charite Universitätsmedizin, Berlin, Germany; University of Tuebingen and Kantonsspital St. Gallen, St. Gallen, Switzerland; Fachpraxis, Frankfurt, Germany; UFK Frankfurt/Main, Frankfurt/Main, Germany; Barbaraklinik, Hamm, Germany; University of Schleswig-Holstein, Kiel, Germany; Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Luebeck, Germany; Onkologische Schwerpunktpraxis, Bielefeld, Germany; Mutterhaus der Boromaerinnen,
| |
Collapse
|
6
|
Coombes RC, Von Minckwitz G, Hicks J, Klare P, Evans AA, Schmidt M, Makris A, Grieve R, Loibl S, Maher L, Mousa K, Buchsenscuhtz K, A'Hern R, Bliss JM. A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps115] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Denkert C, Kronenwett R, Loibl S, Nekljudova V, Darb-Esfahani S, Gerber B, Sinn B, Petry C, Bauerfeind I, Budczies J, Rezai M, Dietel M, Schrader I, Kunz G, Von Minckwitz G. RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10526] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Loibl S, Bruey J, Von Minckwitz G, Huober JB, Press MF, Darb-Esfahani S, Solbach C, Denkert C, Tesch H, Holms F, Fehm TN, Mehta K, Untch M. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.530] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Von Minckwitz G, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, Du Bois A, Huober JB, Hanusch CA, Konecny GE, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1028] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Wenners AS, Mehta K, Loibl S, Park H, Arnold N, Hamann S, Weimer J, Ataseven B, Schem C, Khandan F, Thomssen C, Jonat W, Holzhausen H, Von Minckwitz G, Denkert C, Bauer M. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Heitz F, Sinn B, Loibl S, Du Bois A, Jackisch C, Kuemmel S, Denkert C, Barinoff J, Mehta K, Von Minckwitz G. Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Conrad B, Harbeck N, Von Minckwitz G, Wuellner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Loibl S. SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Budczies J, Denkert C, Mueller B, Brockmoeller SF, Dietel M, Radke C, Loibl S, Von Minckwitz G, Griffin JL, Oresic M, Wohlgemut G, Fiehn O. Separation of breast cancer from normal tissues using GC-MS-based metabolite profiling. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Goss PE, Barrios CH, Chan A, Chia SKL, Delaloge S, Ejlertsen B, Ingle JN, Moy B, Iwata H, Holmes FA, Mansi J, Von Minckwitz G, Han L, Thiele A, Agrapart V, Freyman A, Truscello J, Berkenblit A, Finkelstein D. A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Gerber B, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch CA, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober JB, Hauschild M, Loibl S, Nekljudova V, Untch M, Von Minckwitz G. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1006] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching PA, Barinoff J, Holms F, Thomssen C, Zahm DM, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, Von Minckwitz G. Rechallenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Hanker LC, Sänger N, Holtrich U, Kaufmann M, Darb-Esfahani S, Nekljudova V, Von Minckwitz G. Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Thorsten K, Bauerfeind I, Fehm T, Fleige B, Gisela H, Lebeau A, Liedtke C, Mai M, Von Minckwitz G, Schrenk P, Staebler A, Untch M. Abstract P1-01-04: Axillary Intervention in Patients Undergoing Neoadjuvant Therapy (NST) — First Results from the SENTINA Study. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-01-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The optimal scheduling for sentinel lymph node biopsy (SLNB) among patients with breast cancer undergoing neoadjuvant systemic therapy (NST) is unclear. SENTINA-study is the first prospective multicenter trial that systematically examines the feasibilty and reliability of SLNB prior to and after (NST). Here we present results of a first exploratory analysis by examining distribution of N-stages in the different treatment arms and correlating the axillary status with the type of breast surgery (breast conserving therapy [BCT] vs mastectomy [ME]).
Methods: The SENTINA study is a four-arm multicenter (n= XXX) observation study. Patients will be stratified based on their clinical lymph node status prior to treatment. If the lymph node status is clinically negative SLNB is performed before NST. Patients with a negative SLN will undergo no further axillary surgery (Arm A), whereas patients with a positive SLN will be treated with sentinel-node-guided axillary dissection (SLNB-AD) after NST (Arm B). If the lymph node is clinically positive upon initial presentation, patients will undergo NST prior to any axillary intervention. If patients convert to a clinically negative lymph node status through NST they will undergo SLNB-AD (ARM C). Patients with persistent positive nodes or whose tumors progress under NST undergo primary axillary dissection (Arm D). Clinically node positive patients will be endcouraged to undergo FNA to confirm their lymph node status. A total of 1508 patients in the entire study will be needed to calculate the false-negative rate in this group with a one-sided 95% confidence interval not exceeding 10%.
Results: 873 patients have been accrued into SENTINA until may 31th 2010, 523 (59,9%) have completed their treatment. 180 (34,4%) women have been treated in Arm A and 117 (22,4%) in Arm B. In 170 (32,5%) patients the clinical axillary status converted from a clinical positive to a clinical negative status (Arm C). In 65 pts (12,4%) the axillary status remained positive or the tumor progressed under NCHT (Arm D). BCT rates in Arm A-D were 88.3%, 75.2%, 61.8% and 22.2% respectively.
Conclusion: First results of the SENTINA study show a strong correlation between the axillary status and the type of breast surgery in patients, who are treated with NST. Importantly, we demonstrate that the clinical assessment of the axillary status is unprecise. There is an urgent need to optimize the tailoring of axillary intervention in the setting of NST
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-01-04.
Collapse
Affiliation(s)
- K Thorsten
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - I Bauerfeind
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - T Fehm
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - B Fleige
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - H Gisela
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - A Lebeau
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - C Liedtke
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - M Mai
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - G Von Minckwitz
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - P Schrenk
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - A Staebler
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - M. Untch
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| |
Collapse
|
19
|
Thomssen C, Kantelhardt EJ, Plueckhahn K, Veyret C, Augustin D, Hanf V, Paepke D, Meisner C, Von Minckwitz G, Harbeck N. Report of toxicities from the multicenter, randomized NNBC 3-Europe trial: 6xFEC versus 3xFEC-3xDoc for high-risk node-negative breast cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Von Minckwitz G. ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophospamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps104] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Darb-Esfahani S, Kronenwett R, Von Minckwitz G, Kuemmel S, Budczies J, Rody A, Gehrmann M, Denkert C, Du Bois A, Loibl S. Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10514] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Kaufmann M, Eiermann W, Schuette M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Loibl S, Nekljudova V, Von Minckwitz G. Long-term results from the neoadjuvant GeparDuo trial: A randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.537] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Loibl S, Mueller B, Von Minckwitz G, Blohmer JU, Bois AD, Huober JB, Fend F, Budczies J, Denkert C. PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10511] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Kantelhardt EJ, Thomssen C, Vetter M, Meisner C, Schmidt M, Martin P, Sweep F, Von Minckwitz G, Schmitt M, Harbeck N. Molecular types and prognostic markers uPA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Kühn T, Bauerfeind I, Fehm TN, Fleige B, Helms G, Liedtke C, Mai M, Von Minckwitz G, Staebler A, Untch M. Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Von Minckwitz G, Untch M, Nueesch E, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, Blohmer JU, Loibl S, Jueni P. Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Von Minckwitz G, Bauerfeind I, Gerber B, Eidtmann H, Kaufmann M, Costa SD, Loibl S, Nekljudova V, Untch M. Geparquinto: An interim safety analysis of epirubicin/cyclophosphamide followed by docetaxel with or without bevacizumab as neoadjuvant chemotherapy for primary breast cancer patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e11519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11519^ Background: The GeparQuinto trial is investigating the incorporation of bevacizumab (B), RAD001 (everolimus) for HER2-negative, and lapatinib for HER2-positive patients (pts) into neoadjuvant treatment regimens. As these targeted agents have not yet been adequately tested in combination with epirubicin (E), cyclophosphamide (C), and docetaxel (T) chemotherapy, a run-in phase of the trial was conducted for safety reasons. Methods: Starting in 11/2007, 62 pts received 4 cycles of E: 90 mg/m2 and C: 600 mg/m2, both on day 1 q day 21 followed by 4 cycles of T: 100 mg/m2, day 1 q day 21. Pts were randomized to receive this chemotherapy alone (EC-T, n=32) or concomitantly with B: 15 mg/kg i.v., day 1 q day 21 (ECB-TB, n=30). Main eligibility criteria for this part of the study were: histologically confirmed, HER2-negative, locally advanced breast cancer (cT3 cN+ and cT4), female, and ≥18 years of age with normal cardiac function (LVEF >55%). This interim toxicity analysis was a prerequisite for opening the main phase of the HER2-negative trial part to also include pts with cT2 tumors. Results: 61 pts received all cycles of EC (n=31 EC-T, n=30 ECB-TB), 1 pt discontinued on investigator's decision, 1 pt discontinued after EC due to disease progression. 18 pts received all cycles of T in each of the EC-T and ECB-TB groups. Reasons for discontinuation of T were adverse events (n=2 EC-T, n=1 ECB-TB) or investigator's decision (n=1 EC-T). 17 pts completed all cycles of B. Statistically significant differences in toxicities were only observed for grade 3–4 leucopenia during EC (40.6%) and ECB (70.0%; p=0.024) and for grade 1–4 [grade 3–4] mucositis during T (52.4% [9.5%]) and TB (100% [36.8%]; p<0.001 [p=0.060]). No statistically significantly different levels of other hematological or non-hematological toxicities were reported between the two arms. Conclusions: Addition of B to EC followed by T is feasible with the only increase in toxicity due to leucopenia and mucositis. Based on these data, the main phase of the trial was opened and has included over 450 pts to date. [Table: see text] ASCO Conflict of Interest Policy and Exceptions In compliance with the guidelines established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519–521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the ASCO Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, consultant or advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520). The ASCO Conflict of Interest Policy disclosure requirements apply to all authors who submit abstracts to the Annual Meeting. For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract will be ineligible for placement in the 2009 Annual Meeting unless the ASCO Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research. NIH-sponsored trials are exempt from the Policy restrictions. Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings. For more information about the ASCO Conflict of Interest Policy and the exceptions process, please visit www.asco.org/conflictofinterest .
Collapse
Affiliation(s)
- G. Von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| | - I. Bauerfeind
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| | - B. Gerber
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| | - H. Eidtmann
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| | - M. Kaufmann
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| | - S. D. Costa
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| | - S. Loibl
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| | - V. Nekljudova
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| | - M. Untch
- German Breast Group, Neu-Isenburg, Germany; Frauenklinik, Landshut, Germany; Universitätsfrauenklinik, Rostock, Germany; Unifrauenklinik, Kiel, Germany; Unifrauenklinik, Frankfurt, Germany; Unifrauenklinik, Magdeburg, Germany; Helios Klinikum, Berlin, Germany
| |
Collapse
|
28
|
Rody A, Holtrich U, Gaetje R, Engels K, Von Minckwitz G, Loibl S, Ruckhäberle E, Ahr A, Karn T, Kaufmann M. Contribution of tumor-associated lymphocytes to a niche for “stem cell-like” breast cancer cells. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Untch M, Fasching PA, Bauerfeind I, Conrad U, Camara O, Fett W, Kuzeder W, Lück H, Loibl S, Von Minckwitz G. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.517] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh FE, Kaufmann M, Loibl S. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1025] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Loibl S, Ring A, Von Minckwitz G, Lenhard M, Amant F, Weiss C, Augustin D, Nekljudova V, Kaufmann M. Breast cancer during pregnancy—A prospective and retrospective European registry (GBG-20/BIG02–03). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22143] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Schwenkqlenks M, Von Minckwitz G, Lyman G, Lopez-Pousa A, Bacon P, Lawrinson S, Aapro M. Febrile neutropenia, related hospitalizations and chemotherapy delivery in breast cancer patients younger than 65 years receiving pegfilgrastim primary prophylaxis vs current practice neutropenia management. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)70378-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
33
|
Aapro M, Schwenkglenks M, Lyman G, Lopez-Pousa A, Easton V, Skacel T, Von Minckwitz G. 2033 ORAL Improved chemotherapy delivery in breast cancer patients receiving pegfilgrastim primary prophylaxis compared with current practice neutropenia management – results from an integrated analysis (NeuCuP). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70795-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
34
|
Pegram M, Forbes J, Pienkowski T, Valero V, Eiermann W, Von Minckwitz G, Martin M, Crown J, Taupin H, Slamon D. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.lba1008] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA1008 Background: Based on preclinical synergism between docetaxel (T), carboplatin (C) and trastuzumab (H), BCIRG conducted a phase III trial in HER2-positive MBC to evaluate efficacy and safety of H in combination with T or TC. Methods: 263 patients (pts) with HER2 FISH+ MBC were randomized to TH (H with T 100mg/m2) or TCH (H with T 75mg/m2 and C AUC=6). Chemotherapy was given every 3 weeks (q3w) for 8 cycles with weekly H at 2mg/kg (loading dose of 4 mg/kg) followed by H q3w at 6 mg/kg until progression. Pts were stratified by centre and prior (neo) adjuvant taxane chemotherapy. Primary endpoint was Time To disease Progression (TTP). Secondary endpoints include overall survival, response rate, duration of response (DR), clinical benefit (CB) and safety. Results: 131 pts were treated in each arm Pt characteristics were well balanced in both groups. A first efficacy analysis was conducted at 204 events. There was no significant difference between TH and TCH in median TTP (11.1 vs 10.4 mos, p=0.57), ORR (73% in both arms), DR (10.7 vs 9.4 mos) and CB (67% in both arms). At 39 months of median follow-up, median overall survival was 36.40 and 36.57 months in TH and TCH arms respectively. More patients on TCH received the max number of chemotherapy cycles, and numerically fewer patients on TCH discontinued treatment as a result of non hematological toxicity. The most common gr 3/4 toxicities were: Neutropenic infection that was 16.8% vs 9.2% respectively for TH and TCH, thrombocytopenia (2% vs 15%), asthenia (5% vs 12%), anemia (5% vs 11%), and diarrhea (2% vs 10%). Two pts died (1.5%) due to sepsis in TCH. Absolute LVEF decline > 15 % were seen in 5.5 % vs 6.7 % of pts. One pt (0.8%) had a symptomatic CHF in TH arm. Conclusion: Both TH (T 100) and TCH (T 75) were highly effective treatment regimens in women having HER2-positive MBC, demonstrating high response rates, median TTP > 10 months, and median overall survival > 36 months in both TH and TCH. Cardiac toxicity was no significant problem with either treatment. [Table: see text]
Collapse
Affiliation(s)
- M. Pegram
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - J. Forbes
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - T. Pienkowski
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - V. Valero
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - W. Eiermann
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - G. Von Minckwitz
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - M. Martin
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - J. Crown
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - H. Taupin
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| | - D. Slamon
- UCLA Geffen School of Medicine, Los Angeles, CA; University of Newcastle, Newcastle, Australia; M-S. Curie Centre, Warsaw, Poland; MD Anderson Cancer Center, Houston, TX; Frauenklinik vom Roten Kreuz, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; ICORG, Dublin, Ireland; CIRG, Paris, France
| |
Collapse
|
35
|
Minckwitz GV, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Loibl S. Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from 278 patients with cT4a-d tumors of the GeparTRIO trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
542 Background: Neoadjuvant chemotherapy is the treatment of choice in patients with T4a-c and inflammatory (T4d) breast cancer. However, data on large-scale, multicentre, prospective trials are missing. In the GeparTRIO study (SABCS 2006, abstr. 42) 278 of 2,090 patients with cT4a-c or T4d tumors were included as a separate stratum for inoperable disease for a prospectively planned analysis. Methods: Patients were treated with 2 cycles TAC (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2, q d 21). If tumor reduction was >50%, patients were randomized to receive 4 or 6 additional TAC cycles. If tumor reduction was less, patients were randomized to 4 additional TAC cycles or to 4 NX cycles (vinorelbine 25 mg/m2 day 1 + 8, capecitabine 2,000 mg/m2 day 1 14, q21). Efficacy endpoints were pCR-rate (no invasive and no non-invasive residuals in breast and lymph nodes) (primary), clinical response before surgery and breast conserving therapy (BCT) rate (secondary). Results: 95 (4.6%) T4d, 183 (8.9%) cT4a-c, and 1,767 (86.4%) T1–3 tumors were registered in GeparTRIO within 36 months. Patients with inoperable/operable tumors had a median age of 53.9/49.0 years, median cT size: 7.0/4.0cm, cN+: 75.6/52.0%, ductal: 76.3/78.4%, lobular: 14.0/13.5%, multiple lesions: 28.5/19.5%, grade 3: 34.8/39.9%, hormone receptor (HR) neg: 24.7/36.6%, HER-2 pos: 41.0/35.5%. Response rates for T4d, T4a-c, T1–3 were 8.4, 10.9, 17.5% (pCR, p=0.007), 36.7, 59.4, 72.6% (palpation after 2 cycles TAC, p<0.0001), 64.2, 62.3, 77.8% (palpation before surgery, p<0.0001), 52.6, 51.9, 67.4% (ultrasound before surgery, p<0.0001). BCT was performed in 12.6, 31.7, 69.5% (p<0.0001). Response after two cycles, negative HR content, young age, high grade, ductal type, but not tumor stage or size, were independent predictors for pCR in the total population. Conclusions: Inflammatory and cT4a-c breast carcinomas, compared to cT1–3 tumors, show less favorable tumor characteristics but a comparable pattern of response to TAC/NX. These patients do not need separate neoadjuvant trials. [Table: see text]
Collapse
Affiliation(s)
- G. Von Minckwitz
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - S. Kümmel
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - P. Vogel
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - C. Hanusch
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - H. Eidtmann
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - J. Hilfrich
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - B. Gerber
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - J. Huober
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - S. D. Costa
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| | - S. Loibl
- German Breast Group, Neu Isenburg, Germany; Universitäts-Frauenklinik, Essen, Germany; Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Frauenklinik vom Roten Kreuz, München, Germany; Universitäts-Frauenklinik, Kiel, Germany; Henrietten Stiftung, Hannover, Germany; Universitäts-Frauenklinik, Rostock, Germany; Universitäts-Frauenklinik, Tübingen, Germany; Universitäts-Frauenklinik, Magdeburg, Germany; Universitäts-Frauenklinik, Frankfurt, Germany
| |
Collapse
|
36
|
Forbes JF, Pienkowski T, Valero V, Eiermann W, Von Minckwitz G, Martin M, Smylie M, Crown JM, Noel N, Pegram M. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.lba516] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA516 Background: Based on preclinical synergism between docetaxel (T), carboplatin (C) and trastuzumab (H), BCIRG conducted a phase III trial for women with HER2+ MBC to evaluate efficacy and safety of H in combination with T or TC. Methods: 263 patients (pts) with HER2 FISH+ MBC were randomized to TH, (H with T 100 mg/m2) or TCH, (H with T 75 mg/m2 and C AUC=6). Chemo was given q3 wks for 8 cycles with wkly H at 2 mg/kg (loading dose of 4 mg/kg), followed by H q3 wks at 6 mg/kg until progression. Pts were stratified by centre and prior (neo) adjuvant taxane chemotherapy. Primary endpoint was TTP with 80% power (0.05 significance) to detect a 50% improvement in median TTP between the 2 arms. Secondary endpoints include overall survival, response rate, duration of response (DR), clinical benefit (CB) and safety. Results: 131 pts were treated in each arm. Pt characteristics were well balanced in both groups. Importantly, only 52% of pts received C at the protocol specified dose (RDI > 0.9). Efficacy analysis was conducted at 204 events. There was no significant difference between TH and TCH in median TTP (11.1 vs 10.4 mos, p = 0.57), ORR (73% in both arms), DR (10.7 vs 9.4 mos) and CB (67% in both arms). The most common gr 3/4 toxicities were: infection (44% vs 30%), neutropenic infection (22% vs 12%), thrombocytopenia (2% vs 15%), febrile neutropenia (12% vs 13%) asthenia (5% vs 12%), anemia (5% vs 11%), and diarrhea (2% vs 9%). Two pts died (1.5%) due to sepsis in TCH. Absolute LVEF decline > 15% were seen in 5.5% vs 6.7% of pts. One pt (0.8%) had a symptomatic CHF in TH arm Conclusions: The already effective TH regimen does not benefit from the addition of C, when the T dose in TH is 100 mg/m2 and 75 mg/m2 in TCH, in women with HER2+ MBC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. F. Forbes
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - T. Pienkowski
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - V. Valero
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - W. Eiermann
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - G. Von Minckwitz
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - M. Martin
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - M. Smylie
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - J. M. Crown
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - N. Noel
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| | - M. Pegram
- University of Newcastle ANZ BCTG, Newcastle, Australia; M-S Curie Centre, Warsaw, Poland; M. D. Anderson Cancer Center, Houston, TX; Frauenklinik vom RK, Munchen, Germany; Universitatsklinikum, Frankfurt, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; ICORG, Dublin, Ireland; CIRG, Paris, France; UCLA, Los Angeles, CA
| |
Collapse
|
37
|
Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, Von Minckwitz G. Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.547] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
547 Background: Initial adjuvant treatment with anastrozole has significant efficacy and tolerability advantages over tamoxifen in postmenopausal women with hormone-sensitive early breast cancer (EBC) (ATAC Trialists’ Group. Lancet 2005; 365: 60–62). The ARNO 95 study evaluated prospectively switching to anastrozole from tamoxifen after 2 years, compared with continuing tamoxifen therapy. Here, we present an interim efficacy and safety analysis. Methods: This was a prospective, randomized, open-label study conducted in 54 centers in Germany. Postmenopausal women (≤75 years) with hormone receptor-positive, invasive EBC, who had received 2 years of adjuvant tamoxifen without recurrence, were randomized to switch to anastrozole (1 mg/day) or continue on tamoxifen (20 or 30 mg/day) for a further 3 years. No adjuvant chemotherapy was given. The primary end point was disease-free survival (DFS; time to earliest occurrence of local or distant recurrence, new primary breast cancer, or death from any cause); secondary end points included overall survival (OS), safety, and tolerability. Data were analyzed using a log-rank test; a second analysis used a Cox proportional hazards model with covariates of age, tumor size, nodal status, grade, and type of surgery. Results: Overall, 979 patients (mean age 60 years; 74% node-negative; 97% hormone receptor-positive) were enrolled, 489 were randomized to switch to anastrozole, with 490 continuing on tamoxifen. Median follow-up was 30.1 months. Switching to anastrozole significantly improved DFS and OS compared with continuing on tamoxifen ( Table ). Fewer patients who switched to anastrozole reported serious adverse events (22.7%) compared with those who remained on tamoxifen (30.8%). Conclusions: Switching endocrine treatment improved DFS and OS in this well-defined population. Postmenopausal women with hormone-sensitive EBC who have already received 2 years’ adjuvant tamoxifen therapy should be switched to anastrozole. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- M. Kaufmann
- Klinik Fur Gynakologie und Geburtshilfe, Frankfurt, Germany; Universitatsklinikum, Kiel, Germany; Krankenhaus Henriettenstiftung, Hannover, Germany; University of Magdeburg, Magdeburg, Germany; Creative Reserach Solutions, Wiesbaden, Germany; University Hospital, Frankfurt, Germany
| | - W. Jonat
- Klinik Fur Gynakologie und Geburtshilfe, Frankfurt, Germany; Universitatsklinikum, Kiel, Germany; Krankenhaus Henriettenstiftung, Hannover, Germany; University of Magdeburg, Magdeburg, Germany; Creative Reserach Solutions, Wiesbaden, Germany; University Hospital, Frankfurt, Germany
| | - J. Hilfrich
- Klinik Fur Gynakologie und Geburtshilfe, Frankfurt, Germany; Universitatsklinikum, Kiel, Germany; Krankenhaus Henriettenstiftung, Hannover, Germany; University of Magdeburg, Magdeburg, Germany; Creative Reserach Solutions, Wiesbaden, Germany; University Hospital, Frankfurt, Germany
| | - H. Eidtmann
- Klinik Fur Gynakologie und Geburtshilfe, Frankfurt, Germany; Universitatsklinikum, Kiel, Germany; Krankenhaus Henriettenstiftung, Hannover, Germany; University of Magdeburg, Magdeburg, Germany; Creative Reserach Solutions, Wiesbaden, Germany; University Hospital, Frankfurt, Germany
| | - G. Gademann
- Klinik Fur Gynakologie und Geburtshilfe, Frankfurt, Germany; Universitatsklinikum, Kiel, Germany; Krankenhaus Henriettenstiftung, Hannover, Germany; University of Magdeburg, Magdeburg, Germany; Creative Reserach Solutions, Wiesbaden, Germany; University Hospital, Frankfurt, Germany
| | - I. Zuna
- Klinik Fur Gynakologie und Geburtshilfe, Frankfurt, Germany; Universitatsklinikum, Kiel, Germany; Krankenhaus Henriettenstiftung, Hannover, Germany; University of Magdeburg, Magdeburg, Germany; Creative Reserach Solutions, Wiesbaden, Germany; University Hospital, Frankfurt, Germany
| | - G. Von Minckwitz
- Klinik Fur Gynakologie und Geburtshilfe, Frankfurt, Germany; Universitatsklinikum, Kiel, Germany; Krankenhaus Henriettenstiftung, Hannover, Germany; University of Magdeburg, Magdeburg, Germany; Creative Reserach Solutions, Wiesbaden, Germany; University Hospital, Frankfurt, Germany
| |
Collapse
|
38
|
Rody A, Holtrich U, Müller V, Gaetje R, Diallo R, Gehrmann M, Von Minckwitz G, Engels K, Karn T, Kaufmann M. c-kit: Identification of co-regulated genes by gene expression profiling and clinical relevance of two breast cancer subtypes with stem cell like features. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.622] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
622 Background: Expression of the proto-oncogene c-kit has been found in malignant tissue including a subset of breast cancers. c-Kit is also expressed in normal breast tissue and several authors found a loss of c-kit expression in breast carcinoma suggesting it might be involved in the growth control of mammary epithelium. Until now, only a few markers were described to be co-regulated with c-kit. To elucidate the possible role of c-kit in malignant transformation, we analyzed gene expression data of breast cancer patients. Methods: Tumor tissue of n=171 breast cancer patients were analyzed by gene expression profiling using Affymetrix Hg U133 Arrays (22,500 genes) and bioinformatic analyses. Tumor samples with high stromal and low epithelial cell content by gene expression profiling were excluded for further analysis. Validation was performed with n=100 independent samples. Results: A total of 10.5% of the tumors showed strong c-kit expression (2.5 fold above median). A careful dissection of global expression data revealed strong correlations of c-kit with the expression of a large cluster of genes containing several for whom c-kit coexpression was already described (HER1, CK-5/-17, PDGFR) as well as several members of the wnt signalling pathway, providing a possible novel link to mammary epithelial differentiation. Analysis of n=171 breast cancer samples according to this gene set allows the identification of putative “stem cell like” tumors (SCL) characterized by expression of several known stem cell markers. Surprisingly, a tight link of ER status and proliferation is restricted only to these SCL tumors but lost among non-SCL tumors. The clinical implications of our findings will be presented. Conclusions: For the first time these data bring together the description of two breast cancer subtypes identified by gene expression profiling with the actual stem cell model of the development of breast cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Rody
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - U. Holtrich
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - V. Müller
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - R. Gaetje
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - R. Diallo
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - M. Gehrmann
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - G. Von Minckwitz
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - K. Engels
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - T. Karn
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| | - M. Kaufmann
- University of Frankfurt, Frankfurt, Germany; University of Hamburg, Hamburg, Germany; University of Düsseldorf, Düsseldorf, Germany; Bayer HealthCare AG, Leverkusen, Germany; German Breast Group, Neu-Isenburg, Germany
| |
Collapse
|
39
|
Loibl S, Von Minckwitz G, Elling D, Janni W, Kaufmann M, Vescia S, Eggemann H, Harbeck N, Nekljudova V, Kuemmel S. Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18509] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18509 Background: Elderly patients (pts) are more likely to develop haematological toxicity with anthracycline based regimen. There are no sufficient data available on toxicities especially in elderly pts who are treated by taxane containing regimen. Methods: Four prospective randomised trials in the treatment of primary breast cancer have been combined retrospectively to evaluate the toxicity in pts ≥ 60 treated by a taxane. Pts received either 1: docetaxel/adriamycin/cyclophosphamide (TAC 75/50/600 mg/m2), 2: adriamycin(epirubicin)/cyclophosphamide (A(E)/C: 60(90)/600 mgm2) followed by docetaxel (T: 100 mg/m2) or paclitaxel (P: 175mg/m2), or 3: dose-dense adriamycin/docetaxel (AT dd: 50/75 mg/m2) or 4: epirubicin-paclitaxel in sequence (E-P dd: 90–175 mg/m2). A descriptive analysis was performed in regards to pts and per cycles. In the sequential regimen cycles without taxanes were not considered evaluable. Results: 917 pts median age of 64 (range 60–80) years were included in this pooled analysis. 59 were older than 70 years. In total 3852 cycles of a taxane containing chemotherapy were administered. 378 pts (41.2%) received therapy 1, 332 (36.2%) therapy 2, 121 (13.2%) therapy 3, and 86 (9.4%) therapy 4. A total of 16 % of the pts did not complete treatment. Grade 3–4 neutropenia occurred in 46.2% and febrile neutropenia in 6.1% of the pts, severe anemia (0.8%) and thrombopenia (1.1%) was infrequent. Main non hematological toxicities were (% pts with grade I-IV): fatigue 86; loss of appetite 74; nausea and vomiting 68; mucositis 60; sensory neuropathy; conjunctivitis 45; skin 38; nail 39; fluid retention 36; dyspnea 32. Conclusion: Toxicity of taxanes in pts older than 60 years does not significantly differ from younger pts. Therefore, taxanes as adjuvant or neoadjuvant treatment for primary breast cancer could also be considered in otherwise fit pts in the age group of 60–70. [Table: see text]
Collapse
Affiliation(s)
- S. Loibl
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - G. Von Minckwitz
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - D. Elling
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - W. Janni
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - M. Kaufmann
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - S. Vescia
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - H. Eggemann
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - N. Harbeck
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - V. Nekljudova
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| | - S. Kuemmel
- University Hospital, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; LMU München, München, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; Technical University, München, Germany; Charité, Berlin, Germany
| |
Collapse
|
40
|
Von Minckwitz G, Blohmer J, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa S, Kaufmann M. Comparison of neoadjuvant 6 vs 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2-the GEPARTRIO Study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.576] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
576 Background: Primary breast cancer (BC) patients (P) with early response to neoadjuvant TACx2 (75mg/m, 50 mg/m, 500 mg/m, day 1, q21, supported with (pegylated) G-CSF and epoetin) experience a high pathologic complete remission (pCR) rate after further TACx4 (von Minckwitz et al, Ann Oncol 2005) compared to patients without early response (SABCS 2005, Abst 38). We compared prolongation to 8 cycles of TAC with conventional 6 cycles TAC in the chemosensitive subgroup. Methods: P with operable (T 2 cm by palpation) or locally advanced (T4 or N3, M0) BC were treated with TACx2. If tumor reduction was exceeding 50% according to breast ultrasound, P were randomized to receive either 4 or 6 additional cycles. Endpoints were pCR-rate (no invasive and no non-invasive residuals) (primary), sonographic response before surgery, breast conservation rate, safety and compliance (secondary). To detect an increase in pCR-rate from 20 to 26%, 606 evaluable patients were requested for each arm (α=0.05, β=0.2, one-sided). Results: 2106 P were recruited into the multi-centre, prospective, open-label, randomized GEPARTRIO-trial within 36 months. 1400 P with an early response to TACx2 were randomized with the last patient having surgery in Dec 05. Median clinical tumor size was 4.0 (1.0 - 30.0) cm at study entry. A planned safety and blinded efficacy interim analysis was performed on the first 600 patients (306 TACx6, 294 TACx8). Main toxicities (grade I-IV %TACx6 vs %TACx8) were: anemia (91 vs 93), thrombopenia (39 vs 49), neutropenia (65 vs 75), febrile neutropenia (10 vs 16), infection (29 vs 30), vomiting (42 vs 44), diarrhea (59 vs 52), stomatitis (66 vs 67), conjunctivitis (51 vs 57), allergic reactions (20 vs 14), edema (40 vs 47), asthenia (90 vs 93), hand-foot-syndrome (25 vs 28), nail (43 vs 50), dyspnea (33 vs 37), sensory neuropathy (51 vs 61). Treatment was discontinued early in 165 P (31.0%), 53 (19.8%) P during TACx6 and 112 (42.3%) P during TACx8. Overall pCR was reported in 102 (17.0%) of these patients. Conclusions: TACx8 is associated with moderate increase in toxicity and treatment discontinuations compared to TACx6. Final results on the primary and secondary endpoints will be presented. [Table: see text]
Collapse
Affiliation(s)
- G. Von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - J. Blohmer
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - P. Vogel
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - C. Hanusch
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - H. Eidtmann
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - J. Hilfrich
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - B. Gerber
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - J. Huober
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - S. Costa
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| | - M. Kaufmann
- German Breast Group, Neu-Isenburg, Germany; St. Gertrauden Krankenhaus, Berlin, Germany; HSK, Wiesbaden, Germany; Rot-Kreuz-Krankenhaus, München, Germany; Universitätsfrauenklinik, Kiel, Germany; Henrietten Stift, Hannover, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Tübingen, Germany; Universitätsfrauenklinik, Magdeburg, Germany; Universitätsfrauenklinik, Frankfurt am Main, Germany
| |
Collapse
|
41
|
Rody A, V Minckwitz G, Loibl S, Kaufmann M. [Diagnosis and therapy of breast cancer--meeting highlights ASCO 2005]. Zentralbl Gynakol 2005; 127:389-94. [PMID: 16341983 DOI: 10.1055/s-2005-836805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Affiliation(s)
- A Rody
- Zentrum für Gynäkologie und Geburtshilfe, J.-W.-Goethe-Universität Frankfurt, Frankfurt/Main.
| | | | | | | |
Collapse
|
42
|
Rody A, V Minckwitz G, Loibl S, Kaufmann M. [San Antonio Breast Cancer Symposium -- highlights 2004]. Zentralbl Gynakol 2005; 127:59-65. [PMID: 15800835 DOI: 10.1055/s-2005-836352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
The adjuvant therapy of postmenopausal, hormonereceptor positive breast cancer patients with aromatase inhibitors in ATAC, ABCSG 8/ ARNO 95 and IES trial revealed just a benefit in terms of disease-free survival, but not for over-all survival. Thus MA-17 trial is so far the only study which could demonstrate a survival benefit for node positive disease by "extended adjuvant" therapy with letrozole. Node- and receptorpositive, postmenopausal women show a higher benefit by anthracycline containing chemotherapy in combination with tamoxifen, than by endocrine therapy alone. But tamoxifen should given sequentially to chemotherapy (Intergroup 0100/ SWOG-8814 trial). Adjuvant chemotherapy with three cycles FEC followed by three cycles docetaxel reveals a survival benefit compared to six cycles FEC, especially in women older than 50 years (PACS 01 trial). Furthermore there is evolving evidence that dose-dense, interval shortened chemotherapy is superior to standard chemotherapy in adjuvant setting. The impaired survival of receptornegative, nodalpositive breast cancer patients seems to be converted to a survival improvement compared with receptorpositive patients by modern adjuvant cytotoxic regimens (metaanalysis CALGB 8541, 9344, 9741). In primary systemic chemotherapy survival is strongly associated with the rate of pathohistological complete remissions (NSABP B-27). The combination of cytotoxic drugs has no further influence on survival, but the sequential administration of taxane increases the rate of pCR. A difference in survival stratified by pCR and non-pCR in breast and positive nodal status could not be detected, so that the number of involved lymph nodes seems to be the strongest prognostic factor and is independent of tumor response in the breast. The sentinel node biopsy is a safe and reliable method, but the rate of false negative findings depends on the pathohistological methods (NSABP B-32). The morbidity of this method is low compared with conventional axillary dissection in multicenter studies. Local tumor control is an important parameter which offers a significant survival benefit in all age cohorts.
Collapse
Affiliation(s)
- A Rody
- Klinik für Gynäkologie und Geburtshilfe, J.-W.-Goethe-Universität, Frankfurt, Germany.
| | | | | | | |
Collapse
|
43
|
Di Leo A, Chan S, Paesmans M, Friedrichs K, Pinter T, Cocquyt V, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Von Minckwitz G, Leroy JY, Durbecq V, Isola J, Aapro M, Piccart MJ, Larsimont D. HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel. Breast Cancer Res Treat 2004; 86:197-206. [PMID: 15567936 DOI: 10.1023/b:brea.0000036783.88387.47] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE To evaluate the predictive value of HER-2 in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin (A) or with single-agent docetaxel (T). EXPERIMENTAL DESIGN Patients from this study participated in a phase III clinical trial in which doxorubicin or docetaxel was administered for advanced disease. HER-2 was evaluated by IHC. In all positive cases, FISH was used to confirm the HER-2 positive status. The different cohorts of patients identified by HER-2 were examined to assess a possible relationship between HER-2 status and treatment effect. RESULTS Tumor samples were available for 176 of the 326 patients entered in the clinical trial (54%). HER-2 positivity was observed in 20% of the study population. A statistically significant interaction was found between response rates to the study drugs and HER-2 status, with HER-2 positive patients deriving the highest benefit from the use of T (odds ratio for HER-2 positive patients treated with T = 3.12 (95% CI 1.11-8.80), p = 0.03). The interaction between HER-2 and response rates to A and T was also confirmed by a multivariate analysis. No statistically significant interaction was found between HER-2 and drugs efficacy evaluated in terms of time to progression and overall survival, although in the HER-2 negative cohort A was at least as effective as T in term of overall survival. CONCLUSIONS These results suggest that in HER-2 positive breast cancer patients docetaxel might be more active than doxorubicin, while in HER-2 negative patients doxorubicin might be at least as effective as docetaxel. Although the present results cannot have an impact on current practice, they allow us to formulate the hypothesis that HER-2 positive breast cancer is a heterogeneous disease with regard to sensitivity to anthracyclines and taxanes, and that this might be dependent upon other molecular markers including the p-53 and topoisomerase II alpha genes. This hypothesis is currently being tested prospectively in two different 'bench to bed-side' clinical trials.
Collapse
Affiliation(s)
- A Di Leo
- Jules Bordet Institute, Brussels, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Von Minckwitz G, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B, Brunnert K, Gerber B, Zippel HH, Kaufmann M. Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.534] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. Von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - E. Graf
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - M. Geberth
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - W. Eiermann
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - W. Jonat
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - B. Conrad
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - K. Brunnert
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - B. Gerber
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - H. H. Zippel
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| | - M. Kaufmann
- German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany
| |
Collapse
|
45
|
Costa S, Von Minckwitz G, Jackisch C, Raab G, Blohmer JU, Loehr A, Gerber B, Eidtmann H, Hilfrich J, Kaufmann M. TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Costa
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - G. Von Minckwitz
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - C. Jackisch
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - G. Raab
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - J.-U. Blohmer
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - A. Loehr
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - B. Gerber
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - H. Eidtmann
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - J. Hilfrich
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| | - M. Kaufmann
- St. Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu - Isenburg, Germany; Universitätsfrauenklinik, Marburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; Universitätsfrauenklinik, Charite, Berlin, Germany; Frauenklinik der Horst Schmidt Kliniken, Wiesbaden, Germany; 1 Universitätsfrauenklinik der LMU, Munich, Germany; Universitätsfrauenklinik, Kiel, Germany; Frauenklinik Henriettenstiftung, Hannover, Germany; Obstetrics and Gynecology, University Hospital, Frankfurt, Germany
| |
Collapse
|
46
|
Loibl S, Von Minckwitz G, Kaufmann M. [New aspects of carcinoma of the breast therapy and of gynaecological carcinoma treatment]. ACTA ACUST UNITED AC 2004; 125:346-52. [PMID: 14569516 DOI: 10.1055/s-2003-43042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Dose-dense chemotherapy and high dose chemotherapy have been issued in the adjuvant and primary therapy of breast cancer. Should we use GnRH analogues after chemotherapy in premenopausal women who have not become amenorrheic through chemotherapy? How important are the taxanes in the primary and adjuvant treatment of breast cancer? The optimal screening method for women at high-risk for breast cancer was addressed as one of the most important topics. Primary and recurrent ovarian cancer therapy needs to be improved further. The optimal primary therapy for endometrial cancer and cervical cancer with radiotherapy and/or chemotherapy was another addressed issue.
Collapse
Affiliation(s)
- S Loibl
- Universitätsfrauenklinik Frankfurt am Main, Germany.
| | | | | |
Collapse
|
47
|
Abstract
Primary systemic therapy represents today the standard of care in patients with locally advanced breast cancer and becomes more and more an alternative to adjuvant postoperative chemotherapy in patients with operable breast cancer. In a subset of large randomized trials it could be shown that sequential schedules with more than 4 cycles can reach the highest rates of clinical and histopathological complete remissions. In two randomized trials (NSABP B-27, Geparduo) using 4 cycles of Adriamycin/Cyclophosphamide followed by 4 cycles of Docetaxel significant better results could be obtained in comparison with the referring control arm. New approaches try to further individualize chemotherapy, either using molecular biological tumor factors or the early effect of some chemotherapy cycles. In the Gepartrio study clinical response evaluation after 2 cycles can identify patients with a high or low chance for a histopathological complete remission and further treatment strategies can be developed for these different subgroups.
Collapse
|
48
|
Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14:1227-33. [PMID: 12881384 DOI: 10.1093/annonc/mdg346] [Citation(s) in RCA: 195] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine carbamate with high activity in metastatic breast cancer. This multicenter phase II study was designed to evaluate further the efficacy and safety of capecitabine in patients with metastatic breast cancer previously treated with a taxane-containing regimen. PATIENTS AND METHODS All patients had to have documented progression after paclitaxel- or docetaxel-containing chemotherapy. Treatment comprised 3-week cycles of oral capecitabine 1250 mg/m(2) twice-daily for 14 days followed by a 7-day rest period. RESULTS One hundred and thirty-six patients were enrolled. Disease stabilization occurred in 63 patients (46%) and the overall response rate was 15% (95% confidence interval 10% to 23%), providing an overall tumor control rate of 62%. Median time to progression was 3.5 months, median duration of response was 7.5 months and median overall survival was 10.1 months. Capecitabine was generally well-tolerated: most treatment-related adverse events were grade 1/2 in intensity; grade 3/4 treatment-related adverse events were hand-foot syndrome (13%), diarrhea (8%), vomiting (4%) and nausea (3%). There were no treatment-related deaths. CONCLUSIONS This study confirms that capecitabine achieves a high tumor control rate in heavily pretreated patients with metastatic breast cancer. Due to its favorable safety profile and convenient oral administration, capecitabine can be given as an outpatient therapy. Capecitabine should be considered the reference treatment in this setting based on consistently high efficacy and good tolerability.
Collapse
Affiliation(s)
- P Reichardt
- Robert-Rössle-Klinik, Universitätsklinikum Charité, Humboldt-Universität, Berlin.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Bauknecht T, Hefti A, Morack G, Villena-Heinsen C, Wallwiener D, Elling D, Minckwitz GV, Mansouri K, Blatter J, Breitbach GP. Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer 2003; 13:130-7. [PMID: 12657112 DOI: 10.1046/j.1525-1438.2003.13039.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This phase II study evaluated the activity and toxicity of gemcitabine plus cisplatin as first-line treatment of patients with advanced ovarian cancer. Chemonaive patients >/=60-year-old with FIGO stage IIIC or IV epithelial ovarian carcinoma were enrolled. Patients received cisplatin 75 mg /m2 on day 1 and gemcitabine 1250 mg /m2 on day 1 (before cisplatin) and day 8 of a 21-day cycle. Of 44 female patients (median age, 70 years), 72.7% had stage IIIC disease and 67.4% had a Karnofsky performance status >/=80. Of the 37 response-evaluable patients (35 with measurable lesion[s] >/=2 cm), there were seven (18.9%) pathologic complete responses, two (5.4%) pathologic partial responses, two (5.4%) clinical complete responses, and 12 (32.4%) clinical partial responses, for an overall response rate of 62.2% (95% CI, 44.8%-77.5%), and a pathologic response rate of 24.3% (95% CI, 11.8%-41.2%). Median survival was 27.7 months (95% CI, 14.3-40.8 months). Grade 3/4 neutropenia and thrombocytopenia occurred in 59.5% and 30.2% of patients, respectively, with neutropenic fever in one patient. Grade 3 nausea /vomiting and alopecia occurred in 25.6% and 9.5% of patients, respectively. We conclude that gemcitabine plus cisplatin is active and feasible as first-line treatment of advanced epithelial ovarian cancer in patients >/=60 years. Further clinical trials adding gemcitabine to current standard, first-line treatment seem warranted in younger as well as older patients.
Collapse
Affiliation(s)
- T Bauknecht
- Eli Lilly GmbH Deutschland, Bad Homburg v.d.H, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Von Minckwitz G, Brunnert K, Costa SD, Friedrichs K, Jackisch C, Gerber B, Harbeck N, Junkermann H, Möbus V, Nitz U, Schaller G, Scharl A, Thomssen C, Untch M. [Evidence-based recommendations on primary treatment of carcinomas of the breast]. Zentralbl Gynakol 2002; 124:293-303. [PMID: 12232814 DOI: 10.1055/s-2002-34095] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|